Weight Gain from Psychiatric Medication: Options and GLP-1 Drugs

A change in appetite or weight after treatment is worth discussing openly. Some psychiatric medicines affect hunger, fullness, activity or metabolism. This is not a test of willpower, and you do not need to stop a helpful medicine on your own to show that the problem matters.

Timing is useful but does not establish the whole cause. Sleep, food patterns, physical activity, other medicines and health conditions may also contribute. Bring the weight trend and treatment history so the review can protect both physical health and psychiatric stability.

Average metabolic risks differ. Clozapine and olanzapine have relatively high risks, while some other antipsychotics have lower average risks. Mirtazapine, lithium and valproate can also contribute. These averages do not predict an individual response or identify a safe replacement.

The options include reviewing the psychiatric regimen, addressing nutrition and activity, treating metabolic problems, and considering additional medication when appropriate. Changing an effective psychiatric treatment can carry relapse risks; leaving significant metabolic problems unaddressed also carries risks. The decision needs both considered.

Metformin has evidence for preventing or managing antipsychotic-related weight gain in selected patients. A 2025 consensus guideline supports considering it around antipsychotic initiation in defined circumstances. Its suitability depends on medical factors and monitoring; it is not a universal first step or an online self-treatment instruction. Evidence.

Monitoring may include weight, waist, blood pressure, glucose or HbA1c, and lipids. The antipsychotic monitoring guide explains why these checks matter.

There is randomized trial evidence in selected people taking antipsychotics. It should be described by medicine and study population rather than treated as proof that every weight-loss injection works equally well with every psychiatric medicine.

The 2025 COaST trial tested semaglutide in 31 people taking clozapine who had schizophrenia and obesity. Average weight loss was about 13.9% with semaglutide and 0.4% with placebo over 36 weeks. The study did not identify worsening psychotic symptoms or a change in clozapine concentrations, but its small size limits what can be concluded about safety. Evidence.

The 2025 HISTORI trial included 154 people with schizophrenia taking antipsychotics who also had prediabetes and overweight or obesity. Over 30 weeks, semaglutide improved weight and glycaemic outcomes without worsening the measured mental-health outcomes. This adds evidence in that population; it is not a personal forecast or proof for all diagnoses. Evidence.

Direct evidence specifically addressing weight gain from lithium, valproate or mirtazapine is less established. A person may qualify for weight-management treatment for other medical reasons, but that is different from demonstrating a medicine-specific treatment effect.

Names matter. Ozempic and Wegovy contain semaglutide; Mounjaro contains tirzepatide, which acts at both GIP and GLP-1 receptors. Products, formulations and doses are not interchangeable. Approved indications differ by product and jurisdiction; the treating clinician must confirm the current Indian product information. Evidence.

Current large-scale evidence is reassuring about psychiatric safety overall, but a new symptom still needs assessment. Do not automatically label it either a drug reaction or the original illness. The companion guide to mood, food noise and emotional flatness explains the evidence and what to discuss.

Discuss loss-of-control eating, restriction, purging, repeated fasting, compulsive exercise or fear of weight gain before treatment and during follow-up. A weight measurement alone cannot distinguish improved eating from harmful restriction.

Appetite suppression does not replace eating-disorder care. If eating has become distressing or rigid, assessment should address that pattern rather than simply intensify weight loss. Psychological and nutritional care may be needed alongside medical treatment. Evidence.

Include alcohol, non-prescription medicines and supplements in the medication review. Reduced drinking during GLP-1 treatment does not prove that dependence has resolved. People who may be dependent need a medically supported plan for stopping; the companion article explains alcohol cravings and withdrawal safety.

Avoid making several treatment changes at once without a plan. Otherwise, a change in mood, appetite or sleep becomes harder to interpret and important doses may be missed.

Lithium needs a specific plan. Published reports describe toxicity during semaglutide or tirzepatide treatment. Reduced intake, vomiting and dehydration may contribute, but mechanisms and the size of the risk are uncertain. Both prescribers should know about the combination and agree level, kidney and illness monitoring. New marked tremor, unsteadiness, confusion or significant vomiting needs urgent assessment. See the lithium safety guide. Evidence.

Clozapine and constipation. Clozapine can seriously slow the bowel, and GLP-1 treatment can add gastrointestinal difficulties. Report new constipation promptly. Abdominal pain with swelling, vomiting or inability to pass gas requires urgent assessment rather than waiting for the next appointment. Evidence.

Oral medicines and missed doses. Delayed stomach emptying may affect oral-drug absorption, but it does not imply every psychiatric tablet needs a changed dose. Vomiting and missed tablets can themselves disrupt treatment. Ask the prescriber or pharmacist what to do; do not automatically repeat a vomited tablet or double a dose. After a clozapine interruption, obtain specific restart instructions. Evidence.

Pregnancy and contraception. Discuss pregnancy, breastfeeding and plans to conceive before treatment. Tirzepatide has specific advice for oral contraception because its effectiveness may be reduced. The FAQ below explains the additional precautions to confirm with your clinician. Evidence.

Seek urgent medical help for severe persistent abdominal pain, repeated vomiting with inability to keep fluids down, fainting or severe confusion. For immediate danger or inability to stay safe in India, call 112 or attend emergency care. Evidence.

Regain is common after stopping treatment, although the amount and pace vary. In a semaglutide trial extension, participants regained about two thirds of the weight they had lost over the following year. This does not predict what will happen to a person continuing a particular psychiatric medicine. Evidence.

Discuss a continuing care plan, medical monitoring, food and activity support, affordability and reasons treatment might stop. Protecting psychiatric stability remains part of that plan. Do not respond to returning appetite by stopping psychiatric medication or imposing severe dietary restriction.

• Current and previous psychiatric medicines, including the benefits and difficulties with each
• The weight and appetite timeline, including changes before treatment
• The weight-management product, formulation and prescriber, if already using one
• Recent blood pressure, glucose or HbA1c, lipid and kidney results if available
• Lithium levels or clozapine bowel concerns where relevant
• Sleep, nausea, vomiting, eating patterns, alcohol and any missed doses
• Pregnancy plans, other prescriptions, supplements and practical treatment costs

You do not need to order every test before a first appointment. Bring what you already have; the clinician can identify what is needed. An agreed plan should say who is monitoring each medicine, which symptoms need earlier contact and when the next review will happen.